Scouting for Assets in CNS

Challenge: An early-stage biotechnology company with several assets in pre-clinical development for CNS diseases wanted to supplement its internal pipeline with external innovation. The company...
Learn More

Asset scouting for small molecule assets in CNS

Challenge: An early-stage biotechnology company with several assets in pre-clinical development for CNS diseases wanted to supplement its internal pipeline with external innovation. The company...
Learn More

Asset Scouting for Psychoactive Drugs

Challenge: A biotechnology company with clinical-stage assets positioned in several neuropsychiatric disorders wanted to supplement its internal pipeline with external innovation. The company wanted...
Learn More

Asset scouting for in-licensing opportunities in fibrosis

Challenge: A biotech company focused on developing therapeutics for fibrotic diseases was looking at acquisitions or in-licensing as a way to grow its development pipeline with additional assets....
Learn More

Distressed company analysis for asset scouting

Challenge: Our client was a publicly-traded precision oncology company with whom Alacrita had previously supported with a long-term asset scouting engagement. This cash-rich biotech company wanted to...
Learn More

Scouting in-licensing opportunities for a mid-size pharma company

Challenge: A pharmaceutical company with a proprietary clinical trial technology made the strategic decision to diversify their development arm by acquiring and/or in-licensing pharmaceutical...
Learn More

J.P. Morgan preparation for a biotech with an AI-approach

Challenge: A biotech company with an AI-approach to developing new TCRs for immunotherapy asked Alacrita to assist in preparations for the J.P. Morgan Healthcare conference.
Learn More

Assessing the BD landscape for in-licensing & acquisition deals in GI

Challenge: A private equity client assessing a major investment asked Alacrita to research and assess the business development landscape for potential in-licensing or acquisition deals that could be...
Learn More

Scouting in-licensing targets in inflammation and fibrosis

Challenge: A pharmaceutical company with marketed therapeutics in several respiratory disorders wanted to supplement its internal pipeline with external innovation. The company had already searched...
Learn More

New in-licensing opportunities in inflammation

Challenge A small molecule pharmaceutical incubator is using a novel and proprietary drug discovery and translational platform to develop first-in-class, small molecule therapeutics for the treatment...
Learn More

Sourcing licensing opportunities in oncology & other therapeutic areas

Alacrita provides both in- and out-licensing support to a number of pharmaceutical and biotech organizations and companies. Below you'll find a series of case studies related to this service.
Learn More

Screening for rare disease licensing opportunities

Challenge Our client, a commercial stage biotech company focused on rare and ultra-rare diseases was seeking to build its pipeline of development products. Whilst it had an established business...
Learn More
1 2